This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by How, P. P. Articles by Lau, A. H. Search for Related Content Social Bookmarking                         What's this?

Current Approaches in the Treatment of Chronic Kidney Disease Mineral and Bone Disorder

College of Pharmacy, Department of Pharmacy Practice, University of Illinois at Chicago, Illinois

Darius L. Mason, PharmD, BCPS

College of Pharmacy, Department of Pharmacy Practice, University of Illinois at Chicago, Illinois

Alan H. Lau, PharmD

College of Pharmacy, Department of Pharmacy Practice, University of Illinois at Chicago, Illinois, alanlau{at}uic.edu

Patients with chronic kidney disease (CKD) develop mineral and bone disorder (MBD), a common and important complication, as a result of impaired phosphorus excretion and reduced vitamin D activation. Altered mineral metabolism is now recognized as an independent cardiovascular risk factor in end-stage renal disease patients and contributes to the risk for accelerating vascular calcification. CKD patients are at high risk for cardiovascular disease and vascular calcification which account for the high morbidity and mortality in this patient population. Pharmacotherapeutic interventions are necessary to manage and treat the condition. Multiple classes of agents including phosphorus binders, vitamin D analogs, and calcimimetics are now available to treat CKD-MBD. Recent data have shown that treatment with sevelamer and vitamin D analogs are associated with a reduction in calcification and cardiovascular mortality and improved survival. This article provides an overview of the strategies and considerations for the management of CKD-MBD, as well as their implications on clinical outcomes.

Key Words: chronic kidney disease • secondary hyperparathyroidism • vascular calcification • vitamin D • phosphorus binders

Journal of Pharmacy Practice, Vol. 21, No. 3, 196-213 (2008)
DOI: 10.1177/0897190008315905


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?